156 related articles for article (PubMed ID: 16224736)
1. [Current evidence about atomoxetine. A therapeutic alternative for the treatment of attention deficit hyperactivity disorder].
Velásquez-Tirado JD; Peña JA
Rev Neurol; 2005 Oct 16-31; 41(8):493-500. PubMed ID: 16224736
[TBL] [Abstract][Full Text] [Related]
2. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
3. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
4. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
Davids E; Gastpar M
Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine treatment of attention-deficit/hyperactivity disorder.
Eiland LS; Guest AL
Ann Pharmacother; 2004 Jan; 38(1):86-90. PubMed ID: 14742801
[TBL] [Abstract][Full Text] [Related]
6. [New therapeutic options in the treatment of attention deficit/hyperactivity disorder].
Artigas Pallares J
Rev Neurol; 2004 Feb; 38 Suppl 1():S117-23. PubMed ID: 15011165
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder.
Barton J
Arch Dis Child; 2005 Feb; 90 Suppl 1(Suppl 1):i26-9. PubMed ID: 15665154
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
Prince JB
Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):13-50. PubMed ID: 16321724
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
Wernicke JF; Kratochvil CJ
J Clin Psychiatry; 2002; 63 Suppl 12():50-5. PubMed ID: 12562062
[TBL] [Abstract][Full Text] [Related]
10. [Drugs for attention deficit hyperactivity disorder].
Montañés-Rada F; Gangoso-Fermoso AB; Martíínez-Granero MA
Rev Neurol; 2009 May 1-15; 48(9):469-81. PubMed ID: 19396764
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
[TBL] [Abstract][Full Text] [Related]
12. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
13. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
14. [Attention deficit hyperactivity disorder in adults: a clinical and therapeutic characterization].
Ramos-Quiroga JA; Bosch-Munsó R; Castells-Cervelló X; Nogueira-Morais M; García-Gimenez E; Casas-Brugué M
Rev Neurol; 2006 May 16-31; 42(10):600-6. PubMed ID: 16703528
[TBL] [Abstract][Full Text] [Related]
15. Prepuberal subchronic methylphenidate and atomoxetine induce different long-term effects on adult behaviour and forebrain dopamine, norepinephrine and serotonin in Naples high-excitability rats.
Ruocco LA; Carnevale UA; Treno C; Sadile AG; Melisi D; Arra C; Ibba M; Schirru C; Carboni E
Behav Brain Res; 2010 Jun; 210(1):99-106. PubMed ID: 20156489
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine for attention deficit/hyperactivity disorder.
Garces K
Issues Emerg Health Technol; 2003 May; (46):1-4. PubMed ID: 12751480
[TBL] [Abstract][Full Text] [Related]
17. [Towards an understanding of the molecular mechanisms underlying the pharmacological treatments of attention deficit hyperactivity disorder].
Castellanos FX; Acosta MT
Rev Neurol; 2011 Mar; 52 Suppl 1():S155-60. PubMed ID: 21365598
[TBL] [Abstract][Full Text] [Related]
18. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety.
Heal DJ; Cheetham SC; Smith SL
Neuropharmacology; 2009 Dec; 57(7-8):608-18. PubMed ID: 19761781
[TBL] [Abstract][Full Text] [Related]
19. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.
Wernicke JF; Adler L; Spencer T; West SA; Allen AJ; Heiligenstein J; Milton D; Ruff D; Brown WJ; Kelsey D; Michelson D
J Clin Psychopharmacol; 2004 Feb; 24(1):30-5. PubMed ID: 14709944
[TBL] [Abstract][Full Text] [Related]
20. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]